MA31497B1 - Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c - Google Patents

Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c

Info

Publication number
MA31497B1
MA31497B1 MA32411A MA32411A MA31497B1 MA 31497 B1 MA31497 B1 MA 31497B1 MA 32411 A MA32411 A MA 32411A MA 32411 A MA32411 A MA 32411A MA 31497 B1 MA31497 B1 MA 31497B1
Authority
MA
Morocco
Prior art keywords
hepatitis
methods
virus replication
compound
peptide inhibitors
Prior art date
Application number
MA32411A
Other languages
Arabic (ar)
English (en)
Inventor
Steven W Andrews
Scott Seiwert
Leonid Beigelman
Lawrence Blatt
Brad Buckman
Yutong Jiang
Robert J Kaus
April L Kennedy
Timothy S Kercher
Michael A Lyon
Bin Wang
Kevin R Condroski
Original Assignee
Array Biopharma Inc
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39743068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31497(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc, Intermune Inc filed Critical Array Biopharma Inc
Publication of MA31497B1 publication Critical patent/MA31497B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés de la formule générale (i), ainsi que des compositions, y compris des compositions pharmaceutiques, comprenant un composé de l'invention. L'invention concerne des composés de la formule générale (ii), ainsi que des compostions, incluant des compositions pharmaceutiques, comprenant un composé de l'invention. L'invention concerne en outre des procédés de traitement, y compris des procédés de traitement d'une infection par le virus de l'hépatite c et des procédés de traitement de la fibrose du foie, les procédés impliquant généralement l'administration à un individu qui en a besoin d'une quantité efficace d'un composé ou d'une composition de l'invention.
MA32411A 2007-05-10 2009-12-07 Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c MA31497B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91730007P 2007-05-10 2007-05-10
US2304108P 2008-01-23 2008-01-23
PCT/US2008/063304 WO2008141227A1 (fr) 2007-05-10 2008-05-09 Nouveaux inhibiteurs peptidiques de la réplication du virus de l'hépatite c

Publications (1)

Publication Number Publication Date
MA31497B1 true MA31497B1 (fr) 2010-07-01

Family

ID=39743068

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32411A MA31497B1 (fr) 2007-05-10 2009-12-07 Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c

Country Status (22)

Country Link
US (1) US7932277B2 (fr)
EP (1) EP2185524A1 (fr)
JP (1) JP2010526834A (fr)
KR (1) KR20100027134A (fr)
CN (1) CN101679277A (fr)
AP (1) AP2009005057A0 (fr)
AR (1) AR066528A1 (fr)
AU (1) AU2008251425A1 (fr)
BR (1) BRPI0811447A2 (fr)
CA (1) CA2686546A1 (fr)
CL (1) CL2008001381A1 (fr)
CO (1) CO6241100A2 (fr)
EA (1) EA200971041A1 (fr)
EC (1) ECSP099792A (fr)
IL (1) IL201842A0 (fr)
MA (1) MA31497B1 (fr)
MX (1) MX2009012093A (fr)
NI (1) NI200900205A (fr)
TN (1) TN2009000481A1 (fr)
TW (1) TW200902520A (fr)
WO (1) WO2008141227A1 (fr)
ZA (1) ZA200907858B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
EP2305695A3 (fr) 2005-07-25 2011-07-27 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
CN101415705B (zh) * 2005-10-11 2011-10-26 因特蒙公司 抑制丙型肝炎病毒复制的化合物和方法
EP2185524A1 (fr) 2007-05-10 2010-05-19 Intermune, Inc. Nouveaux inhibiteurs peptidiques de la réplication du virus de l'hépatite c
MX2010011306A (es) 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c.
US8163921B2 (en) * 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20090285774A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AP2011005695A0 (en) * 2008-10-15 2011-06-30 Intermune Inc Therapeutic antiviral poptides.
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010118078A1 (fr) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
MX2012003500A (es) * 2009-09-28 2012-08-01 Intermune Inc Nuevos inhibidores macrocíclicos de la replicación de virus de la hepatitis c.
WO2012047764A1 (fr) * 2010-10-04 2012-04-12 Intermune, Inc. Peptides antiviraux thérapeutiques
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
LT2909205T (lt) 2012-10-19 2016-12-27 Bristol-Myers Squibb Company 9-metilpakeistieji heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4)diazaciklopentadecinilkarbamato dariniai, kaip nestruktūrinės 3 (ns3) proteazės inhibitoriai, skirti hepatito c viruso infekcijų gydymui
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (fr) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014070964A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014070974A1 (fr) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
EA029088B1 (ru) 2013-03-15 2018-02-28 Джилид Сайэнс, Инк. Макроциклические и бициклические ингибиторы вируса гепатита c
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
EA201990069A1 (ru) 2016-06-21 2019-06-28 ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи Производные гетероциклического пролинамида
IL309732A (en) 2021-07-09 2024-02-01 Aligos Therapeutics Inc Antiviral compounds

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547119A (en) * 1967-12-08 1970-12-15 Baxter Laboratories Inc Catheter assembly
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4311137A (en) * 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
US4531937A (en) 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US4511937A (en) * 1983-03-14 1985-04-16 Sony Corporation Inertial tape positioning method and apparatus
NZ216172A (en) 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
US4755173A (en) * 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5232928A (en) 1989-07-25 1993-08-03 Boehringer Ingelheim Pharmaceuticals, Inc. Tetrahydroisoquinoline amides
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5518729A (en) * 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5350562A (en) * 1991-04-09 1994-09-27 Anthony Frank H Method and apparatus for sterilization and separation of plastic and non-plastic medical wastes
DK1302468T3 (da) * 1992-12-29 2009-03-02 Abbott Lab Fremgangsmåder og mellemprodukter til fremstilling af forbindelser, der inhiberer retroviral protease
US5545143A (en) * 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6693072B2 (en) * 1994-06-02 2004-02-17 Aventis Pharmaceuticals Inc. Elastase inhibitors
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6090822A (en) * 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6767991B1 (en) * 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6232180B1 (en) * 1999-07-02 2001-05-15 Taiwan Semiconductor Manufacturing Corporation Split gate flash memory cell
US6232928B1 (en) * 2000-02-03 2001-05-15 Ems Technologies, Inc. Antenna mounting bracket assembly
AU2001251165A1 (en) * 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2001077113A2 (fr) * 2000-04-05 2001-10-18 Schering Corporation Ns3-serine macrocyclique inhibitrice de la protease du virus de l'hepatite c, comprenant des fragments p2 n cycliques
PL358591A1 (en) * 2000-04-19 2004-08-09 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
CN102372764A (zh) * 2000-07-21 2012-03-14 先灵公司 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
BR0115447A (pt) * 2000-11-20 2005-10-18 Bristol Myers Squibb Co Inibidores de tripeptìdeo de hepatite c
FR2821446B1 (fr) * 2001-02-26 2003-06-13 Eads Airbus Sa Dispositif de dialogue d'aeronef, pour dialoguer avec un systeme dudit aeronef
CA2446380A1 (fr) * 2001-05-08 2002-11-14 Yale University Composes proteomimetiques et procedes correspondants
JP4455056B2 (ja) * 2001-07-11 2010-04-21 バーテックス ファーマシューティカルズ インコーポレイテッド 架橋二環式セリンプロテアーゼ阻害剤
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (fr) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques qui agissent contre le virus de l'hepatite c
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370396A1 (fr) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
CA2370400A1 (fr) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (fr) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
SG159385A1 (en) * 2002-04-11 2010-03-30 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
EP1506172B1 (fr) * 2002-05-20 2011-03-30 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US6869964B2 (en) * 2002-05-20 2005-03-22 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis C virus inhibitors
EP1505945B1 (fr) * 2002-05-20 2008-11-05 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c a base de cycloalkyle p1' substitue
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
US20040033959A1 (en) * 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US6848802B2 (en) * 2002-09-18 2005-02-01 Chung-Yang M. Chen Computer light with extensible electric conductive wire
US20040138109A1 (en) * 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
PL199412B1 (pl) * 2002-10-15 2008-09-30 Boehringer Ingelheim Int Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7206600B2 (en) * 2002-12-26 2007-04-17 Intel Corporation Method and apparatus of antenna detection and authentication
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
JP4550824B2 (ja) * 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎抑制化合物
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
RS20050741A (en) * 2003-04-02 2007-06-04 Boehringer Ingelheim International Gmbh., Pharmaceutical compositions for hepatitis c viral protease inhibitors
EP1615949A1 (fr) 2003-04-10 2006-01-18 Boehringer Ingelheim International GmbH Procede pour preparer des composes macrocycliques par reaction de metathese catalysee par complexe de ruthenium
JP4231524B2 (ja) 2003-04-10 2009-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物の製造方法
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7173004B2 (en) 2003-04-16 2007-02-06 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
US20040229848A1 (en) * 2003-05-05 2004-11-18 Hans-Ulrich Demuth Glutaminyl based DP IV-inhibitors
US7273851B2 (en) * 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
OA13187A (en) 2003-07-10 2006-12-13 Achillion Pharmaceuticals Inc Substituted arylthiourea derivatives useful as inhibitors of viral replication.
US7449447B2 (en) * 2003-08-26 2008-11-11 Schering Corporation Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP4685775B2 (ja) 2003-09-18 2011-05-18 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、とりわけｈｃｖｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
EA200600498A1 (ru) 2003-09-22 2006-10-27 Бёрингер Ингельхайм Интернациональ Гмбх Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с
NZ546663A (en) 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
AP2287A (en) 2003-10-14 2011-10-31 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
ES2389201T3 (es) * 2003-10-27 2012-10-24 Vertex Pharmaceuticals Incorporated Mutantes de resistencia de la proteasa NS3/4A de HCV
US7132504B2 (en) * 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005053735A1 (fr) * 2003-11-20 2005-06-16 Boehringer Ingelheim International Gmbh Procede d'elimination de metaux de transition, notamment, a partir de produits de reaction de metathese
US7135462B2 (en) * 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) * 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005056182A1 (fr) 2003-12-08 2005-06-23 Boehringer Ingelheim International, Gmbh Elimination de sous-produit de ruthenium par traitement fluidique supercritique
CN100509784C (zh) * 2003-12-11 2009-07-08 先灵公司 丙型肝炎病毒ns3/ns4a丝氨酸蛋白酶的抑制剂
ES2358333T3 (es) 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
DE602005011402D1 (de) 2004-01-28 2009-01-15 Boehringer Ingelheim Pharma Übergangsmetallnebenprodukte enthaltenden reaktionslösungen
CA2552319C (fr) 2004-01-30 2012-08-21 Medivir Ab Inhibiteurs de la ns-3 serine protease du vhc
EP1711515A2 (fr) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
WO2005085242A1 (fr) * 2004-02-27 2005-09-15 Schering Corporation Nouveaux cetoamides a p4 cycliques en tant qu'inhibiteurs de la ns3 serine protease du virus de l'hepatite c
ATE438622T1 (de) * 2004-02-27 2009-08-15 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
DE602005023224D1 (de) * 2004-02-27 2010-10-07 Schering Corp Neuartige Verbindungen als Hemmer von Hepatitis C-Virus NS3-Serinprotease
CA2557322A1 (fr) * 2004-02-27 2005-09-15 Schering Corporation Inhibiteurs de la protease ns3 du virus de l'hepatite c
BRPI0508867A (pt) 2004-03-15 2007-09-04 Boehringer Ingelheim Int processo para a preparação de compostos macrocìclicos
CN1984922A (zh) * 2004-05-20 2007-06-20 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
CA2568008C (fr) 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Processus de preparation d'inhibiteurs de protease hcv acyclique
US7939538B2 (en) 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
ATE516293T1 (de) 2004-07-16 2011-07-15 Gilead Sciences Inc Antivirale verbindungen
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP4914355B2 (ja) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
MX2007002371A (es) 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
EP1794179A1 (fr) * 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Réaction de métathèse cyclisante en milieu fluide supercritique
EP1794178A1 (fr) 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Procede de fabrication d'inhibiteurs de protease hcv macrocycliques
DE102005002336A1 (de) 2005-01-17 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid
US7323447B2 (en) * 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
US7674612B2 (en) 2005-03-04 2010-03-09 The Rockefeller University Infectious, chimeric hepatitis C virus, methods of producing the same and methods of use thereof
US7608614B2 (en) 2005-03-08 2009-10-27 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
US20060252698A1 (en) 2005-04-20 2006-11-09 Malcolm Bruce A Compounds for inhibiting cathepsin activity
EP1879607B1 (fr) 2005-05-02 2014-11-12 Merck Sharp & Dohme Corp. Inhibiteurs de la protease ns3 du vhc
AU2006250068A1 (en) 2005-05-26 2006-11-30 Schering Corporation Interferon-IGG fusion
WO2006130666A2 (fr) 2005-06-02 2006-12-07 Schering Corporation Medicaments et procedes destines a combiner un inhibiteur de protease hcv et un competiteur akr
WO2006130627A2 (fr) 2005-06-02 2006-12-07 Schering Corporation Methodes de traitement de l'hepatite c
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
CA2611155A1 (fr) 2005-06-02 2006-12-07 Schering Corporation Formulations pharmaceutiques et methodes de traitement employant lesdites formulations
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
WO2006130554A2 (fr) 2005-06-02 2006-12-07 Schering Corporation Methodes de traitement du virus de l'hepatite c
WO2006130553A2 (fr) 2005-06-02 2006-12-07 Schering Corporation Methode destinee au traitement de troubles et de maladies ne repondant pas aux interferons, dans laquelle est utilise un inhibiteur de la protease du vhc
WO2006130686A2 (fr) 2005-06-02 2006-12-07 Schering Corporation Administration d'inhibiteurs de protease du vhc en combinaison avec des aliments pour ameliorer la biodisponibilite
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
EP2305695A3 (fr) 2005-07-25 2011-07-27 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
ES2373685T3 (es) 2005-07-29 2012-02-07 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CN101415705B (zh) 2005-10-11 2011-10-26 因特蒙公司 抑制丙型肝炎病毒复制的化合物和方法
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
BRPI0618610A2 (pt) 2005-11-16 2011-09-06 Hoffmann La Roche derivados de pirrolidina como inibidores de fator xa de coagulação
WO2007092616A2 (fr) 2006-02-09 2007-08-16 Schering Corporation Combinaisons comprenant un ou plusieurs inhibiteurs de protéase du vhc et un ou plusieurs inhibiteurs de polymérase du vhc, et méthodes de traitement associées
JP2009530382A (ja) 2006-03-23 2009-08-27 シェーリング コーポレイション Ｈｃｖプロテアーゼインヒビターとｃｙｐ３ａ４インヒビターとの組み合わせ、および関連する処置方法
KR101059593B1 (ko) * 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US20080187516A1 (en) 2006-06-06 2008-08-07 Ying Sun Acyclic oximyl hepatitis c protease inhibitors
US7728148B2 (en) 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
WO2007145894A2 (fr) 2006-06-08 2007-12-21 Merck & Co., Inc. Procédé rapide pour déterminer la sensibilité aux inhibiteurs de séquences de protéase ns3/4a clonées à partir d'échantillons cliniques
PE20080992A1 (es) 2006-06-26 2008-08-06 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
WO2008008776A2 (fr) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2374812B1 (fr) 2006-07-13 2015-04-15 Achillion Pharmaceuticals, Inc. Peptides de 4-amino-4-oxobutanoyle en tant qu'inhibiteurs de la réplication virale
US7718612B2 (en) 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
WO2008019289A2 (fr) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Inhibiteurs de sérine protéases de l'hépatite c macrocycliques de type tétrazolyle
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20090035267A1 (en) 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US7662779B2 (en) 2006-08-11 2010-02-16 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis C serine protease inhibitors
US20090098085A1 (en) 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US20080038225A1 (en) 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7687459B2 (en) 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US20090035268A1 (en) 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US8343477B2 (en) * 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107623A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080107625A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI406660B (zh) * 2006-11-17 2013-09-01 Tibotec Pharm Ltd Ｃ型肝炎病毒之巨環抑制劑
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2125870A4 (fr) * 2007-02-16 2011-04-06 Boehringer Ingelheim Int Inhibiteurs de la ns3 protéase de l'hépatite c
CA2681624A1 (fr) * 2007-03-23 2009-01-15 Schering Corporation Inhibiteurs de cetoamides de p1 non epimerisables de protease de ns3 du virus de l'hepatite c (vhc)
AU2008240153B2 (en) 2007-04-12 2013-01-31 Joyant Pharmaceuticals, Inc. SMAC mimetic dimers and trimers useful as anti-cancer agents
MX2009011370A (es) 2007-04-24 2009-11-05 Hoffmann La Roche Proceso para el intermediario del inhibidor proteasa de hcv.
US7906513B2 (en) 2007-04-26 2011-03-15 Enanta Pharmaceuticals, Inc. Hydrazide-containing hepatitis C serine protease inhibitors
WO2008134397A1 (fr) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Inhibiteurs à base d'aza-tripeptide de la sérine protéase de l'hépatite c
US20080267917A1 (en) 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US20080274080A1 (en) 2007-04-26 2008-11-06 Yat Sun Or Aza-peptide macrocyclic hepatitis c serine protease inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
US20080274082A1 (en) 2007-04-26 2008-11-06 Yonghua Gai Oximyl hydroxyamic analogs as hepatitis c virus protease inhibitor
US20080317712A1 (en) 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
US7910587B2 (en) 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US20090123423A1 (en) 2007-04-26 2009-05-14 Yonghua Gai Hydroxyamic analogs as hepatitis c virus serine protease inhibitor
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
US20090155209A1 (en) 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
EP2185524A1 (fr) 2007-05-10 2010-05-19 Intermune, Inc. Nouveaux inhibiteurs peptidiques de la réplication du virus de l'hépatite c
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009003009A1 (fr) 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Pyrrolidine substituée utilisée en tant qu'agent anti-infectieux
WO2009005690A2 (fr) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Composés antiviraux
WO2009014730A1 (fr) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase
US20090053175A1 (en) 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
US20090060874A1 (en) 2007-09-05 2009-03-05 Yao-Ling Qiu Bicyclic pyrrolidine derivatives
EP2190858A4 (fr) 2007-09-24 2013-02-13 Achillion Pharmaceuticals Inc Peptides contenant de l'urée en tant qu'inhibiteurs de la réplication virale
US20090082366A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
WO2009076166A2 (fr) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Inhibiteurs oximyles de la sérine protéase de vhc
WO2009085978A1 (fr) 2007-12-20 2009-07-09 Enanta Pharceuticals, Inc. Inhibiteurs de protéase de sérine de virus de l'hépatite c d'oxime carbocyclique couronnés
CN101977915B (zh) 2008-02-04 2014-08-13 埃迪尼克斯医药公司 大环丝氨酸蛋白酶抑制剂
US8211897B2 (en) 2008-02-07 2012-07-03 Virobay, Inc. Inhibitors of cathepsin B
MX2010011306A (es) 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c.
US8211891B2 (en) 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
EP2285822A1 (fr) 2008-05-09 2011-02-23 Boehringer Ingelheim International GmbH Procédé pour la fabrication de macrocycles
AP2011005695A0 (en) * 2008-10-15 2011-06-30 Intermune Inc Therapeutic antiviral poptides.

Also Published As

Publication number Publication date
CL2008001381A1 (es) 2008-11-03
KR20100027134A (ko) 2010-03-10
AU2008251425A1 (en) 2008-11-20
AP2009005057A0 (en) 2009-12-31
NI200900205A (es) 2010-10-11
EP2185524A1 (fr) 2010-05-19
CO6241100A2 (es) 2011-01-20
CA2686546A1 (fr) 2008-11-20
BRPI0811447A2 (pt) 2014-10-29
US20090297476A1 (en) 2009-12-03
TW200902520A (en) 2009-01-16
AR066528A1 (es) 2009-08-26
US7932277B2 (en) 2011-04-26
JP2010526834A (ja) 2010-08-05
ZA200907858B (en) 2012-04-25
WO2008141227A1 (fr) 2008-11-20
CN101679277A (zh) 2010-03-24
IL201842A0 (en) 2010-06-16
ECSP099792A (es) 2010-01-29
MX2009012093A (es) 2010-01-25
EA200971041A1 (ru) 2010-08-30
TN2009000481A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
MA32225B1 (fr) Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
MA29746B1 (fr) Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l'hepatite c
MA33720B1 (fr) Inhibiteurs peptiques cycliques de la replication du virus de l'hépatite c
MA34013B1 (fr) Inhibiteurs du virus de l'hépatite c
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
WO2008005511A3 (fr) Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
BR112012017458A2 (pt) uso de um agente de modificação de hormônio adrenal
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA34837B1 (fr) Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA35404B1 (fr) Composés pour le traitement de la toxicomanie
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
BR112012014899A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
MA31466B1 (fr) Derives de benzimidazole
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA31864B1 (fr) Composés nucléosidiques antiviraux
ES2571730T3 (es) Composiciones farmacéuticas que comprenden droxidopa
MA54386B1 (fr) Modulateurs de trex1
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo